
Press release

Collectis bio research launches first kit from cGPS[®] Custom line for use in human cell lines.

Paris, December 17, 2009 - Collectis bio research, a specialist in genome customization and a subsidiary of Collectis S.A. (Alternext: ALCLS), has today announced the launch of cGPS[®] Custom HEK293, its first research kit that can be used on cell lines derived from human material.

The new cGPS[®] Custom kit will allow scientists to control the expression of any gene of interest in the human embryonic kidney cell line, HEK293. Specifically, the kit allows rapid, efficient and precise gene integration and expression, enabling high quality research into the mechanisms of human gene function and its involvement in disease.

The cGPS[®] Custom HEK293 kit has been initially validated in HEK293 cells, however it also has the potential to be used in any cell line derived from human material. During 2010 Collectis bio research will focus on expanding its series of ready-to-use products for the functional genetics market by validating cGPS[®] Custom HEK293, and its associated simple operating protocols, in other human cell lines.

"We are very excited to reach our goal of launching six new bio research kits this year," said Luc Selig, VP Sales & Marketing for Collectis bio research. *"We are looking forward to bringing a wider range of kits to the market next year"*.

Collectis bio research currently supplies two targeted integration product lines – cGPS[®] (cellular Genome Positioning System) and cGPS[®] Custom – both of which can be purchased via www.collectis-bio research.com.

About Collectis bio research

Collectis bio research was incorporated as a subsidiary of Collectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with genome customization kits for rapid, efficient gene integration at a precise genomic position in a given cell type.

About Collectis S.A.

Collectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in *in vivo* genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Collectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups.

To date, Collectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Collectis, visit our website: www.collectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

CELLECTIS SA

Sylvie Delassus
Senior VP Corporate Communication
+ 33 (0)1 41 83 99 00
media@collectis.com

ALIZE RP

Caroline Carmagnol
+33 (0)6 64 18 99 59
caroline@alizerp.com